MCID: DXR001
MIFTS: 17

Doxorubicin Induced Cardiomyopathy malady

Rare diseases, Cardiovascular diseases categories
Download this MalaCard

Summaries for Doxorubicin Induced Cardiomyopathy

About this section


Fully expand this MalaCard
MalaCards based summary: Doxorubicin Induced Cardiomyopathy is related to sarcoma and neuronitis. Affiliated tissues include heart, bone marrow and bone.

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

About this section

Doxorubicin Induced Cardiomyopathy, Aliases & Descriptions:

Name: Doxorubicin Induced Cardiomyopathy 42


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Rare diseases
Anatomical: Cardiovascular diseases


Related Diseases for Doxorubicin Induced Cardiomyopathy

About this section

Diseases related to Doxorubicin Induced Cardiomyopathy via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

idRelated DiseaseScoreTop Affiliating Genes
1sarcoma10.3
2neuronitis10.2
3vaginitis10.2
4soft tissue sarcoma10.2

Symptoms for Doxorubicin Induced Cardiomyopathy

About this section

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

About this section

Drug clinical trials:

Search ClinicalTrials for Doxorubicin Induced Cardiomyopathy

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

About this section

Anatomical Context for Doxorubicin Induced Cardiomyopathy

About this section

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

32
Heart, Bone marrow, Bone, Testes, Myeloid, Pituitary

Animal Models for Doxorubicin Induced Cardiomyopathy or affiliated genes

About this section

Publications for Doxorubicin Induced Cardiomyopathy

About this section

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50)    (show all 113)
idTitleAuthorsYear
1
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. (24486195)
2014
2
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. (24244825)
2013
3
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. (24338479)
2013
4
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. (24228260)
2013
5
Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. (23741376)
2013
6
The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. (23731918)
2013
7
Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. (22449713)
2012
8
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. (22465037)
2012
9
Discordant impairment of multidirectional myocardial deformation in rats with Doxorubicin induced cardiomyopathy. (22486544)
2012
10
Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone? (21596235)
2011
11
Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation ofA mitochondrial function. (21094500)
2011
12
Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. (22110719)
2011
13
Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. (21330293)
2011
14
Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. (21946105)
2011
15
S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. (22039489)
2011
16
Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. (19920767)
2010
17
Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats. (20004697)
2010
18
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. (20543097)
2010
19
How to protect doxorubicin-induced cardiomyopathy in male albino rats? (20051877)
2010
20
CO liberated from a carbon monoxide-releasing molecule exerts a positive inotropic effect in doxorubicin-induced cardiomyopathy. (19935076)
2010
21
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. (19942623)
2010
22
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. (19010377)
2009
23
Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. (18379782)
2009
24
Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. (18083897)
2008
25
Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. (17928571)
2008
26
Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. (17334414)
2007
27
The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. (17974986)
2007
28
Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. (16449733)
2006
29
Overexpression of Nd1, a novel Kelch family protein, in the heart of transgenic mice protects against doxorubicin-induced cardiomyopathy. (16952015)
2006
30
Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. (16039240)
2005
31
Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. (16364871)
2005
32
Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. (16127512)
2005
33
Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol. (15380672)
2004
34
Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy. (15582323)
2004
35
Molecular biology of doxorubicin-induced cardiomyopathy. (19644577)
2002
36
Doxorubicin-induced cardiomyopathy during pregnancy: three case reports of anesthetic management for cesarean and vaginal delivery in two kyphoscoliotic patients. (12151947)
2002
37
Doxorubicin-induced cardiomyopathy. (10910374)
2000
38
Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry. (10901455)
2000
39
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. (10503942)
1999
40
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. (9848575)
1998
41
The role of iron in doxorubicin-induced cardiomyopathy. (9768818)
1998
42
Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. (9038198)
1997
43
Contractile failure in chronic doxorubicin-induced cardiomyopathy. (9344758)
1997
44
Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. (7817916)
1995
45
Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. (7831179)
1994
46
Etiology of sarcoplasmic reticulum calcium release channel lesions in doxorubicin-induced cardiomyopathy. (1314436)
1992
47
Case presentation of doxorubicin-induced cardiomyopathy: a short- and long-term side effect of pediatric cancer treatment. (1675089)
1991
48
Activity of receptors coupled to guanine nucleotide binding regulatory protein in doxorubicin induced cardiomyopathy. (1660348)
1991
49
Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. (1860214)
1991
50
The efficacy of N-acetylcysteine in preventing doxorubicin-induced cardiomyopathy in dogs. (6836323)
1983

Variations for Doxorubicin Induced Cardiomyopathy

About this section

Expression for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Compounds for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

GO Terms for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Products for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section
  • Antibodies
  • Proteins
  • Lysates

Sources for Doxorubicin Induced Cardiomyopathy

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet